The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Calumet, Inc. (the "Company," "Calumet," "we," "our" or "us") announced today preliminary selected financial results for the year ended December 31, 2025. Based on preliminary data, the Company ...

Asian equities posted a modest gain at the open Tuesday, holding near record levels as geopolitical concerns failed to deter ...

The growth of the Clear Aligner Material Market is primarily driven by rising demand for aesthetic and comfortable ...

When asked about their main challenges in adopting AI over the next two years, C-suite leaders cited data issues as their top ...